1	Balloon Angioplasty as the First-Choice Treatment for Intracranial Atherosclerosis-
2	Related Emergent Large Vessel Occlusion Involving the Microcatheter "First-Pass Effect"
3	
4	Liang Zhang, MM ^{1#} , Xiongjun He, MD ^{2#} , Kaifeng Li, MM ² , Li Ling, MD ² , Min Peng, MM ¹ ,
5	Li'an Huang, MD ^{1*} , Yajie Liu, MD ^{2*}
6	
7	¹ Department of Neurology, First Affiliated Hospital of Jinan University, Guangzhou, China
8	² Department of Neurology, Shenzhen Hospital of Southern Medical University, Shenzhen, China
9	#Contributed equally.
10	
11	*Correspondence:
12	Yajie Liu, MD, Department of Neurology, Shenzhen Hospital of Southern Medical University,
13	NO 1333 Xinhu Rd, Baoan Dt, Shenzhen 518101, China. Email: docliu18@qq.com
14	Li'an Huang, MD, Department of Neurology, First Affiliated Hospital of Jinan University, NO
15	613 West Huangpu Rd, Tianhe Dt, Guangzhou 510630, China. Email: huanglian1306@126.com
16	
17	ABSTRACT
18	Background: It is unknown whether balloon angioplasty can be a first-choice treatment for
19	intracranial atherosclerosis-related emergent large vessel occlusion (ICAS-ELVO) with small
20	clot burden. The microcatheter "first-pass effect" is a valid predictor of ICAS-ELVO with small
21	clot.
22	Objective: To determine balloon angioplasty's efficacy as first-choice treatment for ICAS-ELVO
23	involving the microcatheter "first-pass effect" during endovascular treatment (EVT).

24	Methods: This continuous retrospective analysis assessed ICAS-ELVO patients presenting with
25	the microcatheter "first-pass effect" during EVT. Patients were divided into two first-choice
26	treatment-based groups: preferred balloon angioplasty (PBA) and preferred mechanical
27	thrombectomy (PMT). Efficacy and safety outcomes were compared between groups.
28	Results: Seventy-six patients with ICAS-ELVO involving the microcatheter "first-pass effect"
29	during EVT were enrolled. Compared with patients in PMT group, patients in PBA group were
30	associated with (i) a higher rate of first-pass recanalization (54.0% vs. 28.9%, p=.010) and
31	complete reperfusion (expanded thrombolysis in cerebral ischemia≥2c; 76.0% vs. 53.8%,
32	p=.049), (ii) a shorter puncture-to-recanalization time (49.5 min vs. 56.0 min, p<.001), (iii) less
33	operation costs (48,499.5¥ vs. 99,086.0¥, p<.001),and (iv) more excellent functional outcomes
34	(modified Rankin scale:0-1; 44.0% vs. 19.2%, p=.032) at 90 days. No significant differences in
35	symptomatic intracranial hemorrhage (12.0% vs. 15.4%, p>.999) and mortality (10.0% vs. 7.7%,
36	p>.999) were noted. Logistic regression analysis revealed that first-choice treatment was an
37	independent predictor of 90-day excellent functional outcomes (adjusted odds ratio [aOR] =0.10,
38	95% CI: 0.02–0.66, p=.017).
39	Conclusion: Balloon angioplasty, as the first-choice treatment, potentially improves 90-day
40	functional outcomes for ICAS-ELVO patients with microcatheter "first-pass effect" during
41	EVT.
42	What is already known on this topic : Compared with large vessel occlusion caused by
43	embolization, mechanical thrombectomy has lower recanalization rate, longer procedure time,
44	and poorer prognosis for patients with intracranial atherosclerosis-related emergent large vessel

45 occlusion(ICAS-ELVO).

46 What this study adds : This study revealed that balloon angioplasty, as the first-choice 47 treatment, potentially improves 90-day outcomes, shortens procedure time, and reduces 48 operation costs for patients with ICAS-ELVO involving the microcatheter "first-pass effect" 49 during endovascular treatment. 50 How this study might affect research, practice or policy : We believe that our study makes a significant contribution to the literature because its findings suggest that rapid and accurate 51 52 methods of diagnosing the etiology and clot burden of ELVO as well as the development of an 53 individualized EVT strategy based on etiology and clot burden need to be established. 54 **Keywords:** balloon angioplasty; clot burden; endovascular treatment; intracranial 55 atherosclerosis; mechanical thrombectomy **Abbreviations:** aOR, adjusted odds ratio; CI, confidence interval; CT, computed tomography; 56 57 ELVO, emergent large vessel occlusion; eTICI, expanded thrombolysis in cerebral ischemia; 58 EVT, endovascular treatment; FPR, first pass recanalization; ICAS, intracranial atherosclerosis; 59 IQR, interquartile range; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS, 60 National Institutes of Health Stroke Scale; PBA, preferred balloon angioplasty; PMT, preferred 61 mechanical thrombectomy; PRT, puncture to recanalization time; SD, standard deviation; t-PA, 62 tissue-type plasminogen activator; sICH, symptomatic intracranial hemorrhage. 63

64 **INTRODUCTION**

65 Mechanical thrombectomy (MT) has been the gold-standard of reperfusion therapy for patients

66 with emergent large vessel occlusion (ELVO); however, these studies' participants

67 predominantly originated from Western populations, and the primary etiology of vascular

occlusion was embolism¹⁻⁵. When treating intracranial atherosclerosis-related emergent large 68 69 vessel occlusion (ICAS-ELVO), MT results in a lower recanalization rate, longer procedure 70 times, and poorer outcomes than when treating embolism-induced vessel occlusion, and a significant number of patients require rescue therapy ⁶⁻⁹. Patients with ICAS-ELVO encounter 71 72 unique technical challenges during endovascular recanalization therapy. 73 ICAS-ELVO is related to in-situ atherothrombotic occlusion and usually has a smaller clot burden ¹⁰, for which MT is often inefficient. Moreover, additional and repeated MT tends to 74 75 damage the vascular endothelium and increases the risk of reocclusion. Balloon angioplasty has proven safe in ICAS-ELVO rescue therapy following MT, and we speculate that it may be a 76 77 better first-choice treatment than MT for ICAS-ELVO in patients with a small clot burden. 78 Though certain studies have demonstrated the feasibility of direct angioplasty for patients with ICAS-ELVO¹¹⁻¹⁴, these studies did not define the clot burden of the included patients. The 79 microcatheter "first-pass effect" is considered a valid predictor of ICAS-ELVO¹⁵, and it often 80 81 suggests an occluded vessel with a small clot burden. Thus, we conducted this retrospective 82 study to determine whether balloon angioplasty could be the first-choice treatment for ICAS-83 ELVO in patients with small clot burden, which was defined through the microcatheter "first-84 pass effect" that presented during endovascular treatment (EVT).

85

86 METHODS

87 **Patients**

We reviewed the information of the consecutively collected ELVO patients who underwent
EVT between October 2018 and December 2021 in Shenzhen Hospital of Southern Medical
University. We enrolled patients who:(i) were aged >18 years, (ii) presented with isolated

91	intracranial internal carotid artery (ICA), M1 of middle cerebral artery, intracranial vertebral
92	artery or basilar artery occlusion, and (iii) the microcatheter "first-pass effect" was evaluated
93	before EVT . Patients were divided into two first-choice treatment-based groups: preferred
94	balloon angioplasty (PBA) and preferred mechanical thrombectomy (PMT). A flowchart of the
95	selection process is shown in Figure 1.
96	The etiologies of vessel occlusion and the microcatheter "first-pass effect" were assessed by two
97	neurointerventionalists using clinical and imaging data. The definition of the microcatheter
98	"first-pass effect" has been described in a previous study ¹⁵ , and microcatheters used in this study
99	mainly were the XT-27 [®] (Stryker Inc, Kalamazoo, MI, USA) and Rebar-27 [®] (Medtronic Inc,
100	Minneapolis, MN, USA). Illustrative cases of the microcatheter "first-pass effect" are shown in
101	Figure 2. The basis for determining ICAS-ELVO included: (i) clear evidence of ICAS as the
102	culprit occluded vessel prior to this ischemic event; (ii) procedural evidence of ICAS after the
103	first pass of the microcatheter or balloon dilation/stent deployment; and (iii) significant fixed
104	focal stenosis (stenotic degree \geq 50%) at the occlusion site. To reduce bias, both
105	neurointerventionists were tested in 10 selected cases of ELVO whose etiology was identified as
106	ICAS, and the diagnostic accuracy was 100%. This study was approved by our local medical
107	ethics committee.
108	Endovascular Treatment

109 Our center is a national senior stroke center and has extensive experience in EVT. Patients with

110 intravenous thrombolytic indications were administered t-PA intravenous thrombolytic therapy,

and EVT was performed in patients with intravascular indications after they had provided written

112 informed consent. Decisions regarding recanalization strategies were based on the

113 neurointerventionalists' discretion. When the first-choice treatment failed to recanalize or

114 maintain vascular patency, rescue therapy was performed at the appropriate time. The choice of

balloon size depended on the diameter measured at the proximal segment of the occluded vessel,

and the selected balloon size was generally smaller than the vessel's actual measured diameter.

117 The balloon was gradually pressurized using a pressure pump, and the maximum pressure did

118 not exceed the balloon's pressure. Patients with inadequate preparation for oral antiplatelet

agents received tirofiban before balloon angioplasty and/or stenting. All operations were

120 performed by neurointerventionalists who had > 5 years' EVT experience.

121 Clinical Characteristics and Outcome Assessment

The demographic, clinical, and imaging data of patients were collected from database of the hospital. A head computed tomography (CT) scan was performed within 24 h after surgery to determine the presence of intracranial hemorrhage. Head CT scans were reviewed at any time in patients with early neurological deterioration.

126 The primary efficacy outcome was a postoperative 90-day excellent functional outcome 127 (modified Rankin scale [mRS: 0–1]), which was evaluated at 90 days follow-up reexamination 128 by neurologists who were not involved in the procedure, and telephone-based follow-up was 129 conducted if the patient could not return to the hospital. Secondary efficacy outcomes included 90-day functional independence (mRS 0-2), first-pass recanalization (FPR) rate, successful 130 131 recanalization rate and complete reperfusion rate. FPR is defined as a single thrombectomy, or 132 balloon angioplasty performed to achieve successful recanalization without the use of rescue 133 therapy. Successful recanalization was defined as grade 2b–3 expanded thrombolysis in cerebral ischemia (eTICI), and complete reperfusion was defined as grade 2c-3 eTICI ^{16 17}. The safety 134 135 endpoints were symptomatic intracranial hemorrhage and mortality within 24 h and 90 days after 136 surgery, respectively. Intracranial hemorrhage was assessed using CT, and symptomatic

137	intracranial hemorrhage was defined as neurological deterioration and $a \ge 4$ -point increase in the
138	National Institutes of Health Stroke Scale score on admission (i-NIHSS) ¹⁸ .
139	Statistical Analysis
140	SPSS 20.0 software (IBM Inc, Armonk, NY, USA) was used for statistical analysis. Categorical
141	variables are presented as frequencies (%) and non-normally distributed continuous variables as
142	medians (interquartile ranges [IQRs]). Between-group differences in clinical and procedural
143	characteristics were compared using the χ^2 -test, Student's t-test, Fisher's exact test, or Mann-
144	Whitney U depending on the type of variables analyzed. To evaluate independent predictors of
145	excellent functional outcome at 90 days, we performed a logistic regression model with the

146 following terms in the model: first-choice treatment, i-NIHSS, age, sex, and any other baseline

147 characteristic with a probability value ≤ 0.10 in univariate analyses. All tests were two-tailed,

148 and statistical significance was set at $p \le 0.05$.

149 **RESULTS**

150 Baseline Characteristics and Procedural Details

151 A total of 76 patients were included in the study. Regarding the preferred treatment, 50 patients

underwent balloon angioplasty (PBA group), and 26 underwent MT (PMT group). In the PBA

group, 46.0% (23/50) patients underwent stenting and/or thrombectomy (13 patients underwent

stenting only, five underwent thrombectomy only, and five underwent both stenting and

thrombectomy). In the PMT group, 76.9% (20/26) patients underwent balloon angioplasty and/or

stenting (four patients underwent balloon angioplasty only, one underwent stenting only, and 15

157 underwent both balloon angioplasty and stenting).

158 Baseline characteristics and procedural details are summarized in Table 1. No significant

differences were noted in age, sex, hypertension, diabetes, hyperlipidemia, coronary artery

160	disease, smoking, history of stroke, i-NIHSS, intravenous thrombolysis, glycoprotein IIb/IIIa
161	inhibitor use, general anesthesia, location of vessel occlusion, and time from puncture to first
162	recanalization between the two groups. However, the time from puncture to recanalization (49.5
163	min vs. 56.0 min, p<.001), rescue therapy rate (46.0% vs. 76.9%, p=.010), and operation costs
164	(48,499.5 ¥ vs. 99,086.0 ¥, p<.001) were significantly lower in the PBA group than in the PMT
165	group.

166 **Table 1** Comparison of baseline characteristics and procedural details between the two groups

	Overall	PBA group	PMT group	P value
	(n=76)	(n=50)	(n=26)	
Age (y), mean (±SD)	64.9±10.7	64.6±10.7	65.7±10.8	0.660
Male, n (%)	58 (76.3)	39 (78.0)	19 (73.1)	0.632
Hypertension, n (%)	59 (77.6)	41 (82.0)	18 (69.2)	0.205
Diabetes mellitus, n (%)	33 (43.4)	20 (40.0)	13 (50.0)	0.404
Hyperlipidemia, n (%)	30 (39.5)	18 (36.0)	12 (46.2)	0.390
Coronary artery disease, n (%)	9 (11.8)	6 (12.0)	3 (11.5)	0.633
Smoking, n (%)	20 (26.3)	16 (32.0)	4 (15.4)	0.171
History of stroke, n (%)	21 (27.6)	15 (30.0)	6 (23.1)	0.522
Location of occlusion site, n (%)				0.532
Anterior circulation	49 (64.5)	31 (62.0)	18 (69.2)	
Posterior circulation	27 (35.5)	19 (38.0)	8 (30.8)	
i-NIHSS, median (IQR)	10 (8-13)	10 (8-13)	10 (8-14)	0.930
IV-tPA, n (%)	47 (61.8)	30 (60.0)	17 (65.4)	0.647

Glycoprotein IIb/IIIa	54 (71.1)	35 (70.0)	19 (73.1)	0.779
inhibitor use, n (%)				
General anesthesia, n (%)	38 (50.0)	26 (52.0)	12 (46.2)	0.629
Means of recanalization, n (%)				
Stent retrieval	30 (39.5)	7 (14.0)	23 (88.5)	<0.001**
Aspiration	7 (9.2)	3 (6.0)	4 (15.4)	0.222
Balloon dilation	69 (90.8)	50 (100.0)	19 (73.1)	<0.001**
Stenting	34 (44.7)	18 (36.0)	16 (61.5)	0.034**
Puncture-to-first recanalization	35.0 (29-42.5)	34.5 (27.0-41.0)	38.5 (33.0-45.0)	0.074
time (min), median (IQR)				
Puncture-to-recanalization time	56.0 (34.5-85.5)	49.5 (31.0-70.0)	89.0 (70.0-110.0)	<0.001**
(min), median (IQR)				
Rescue therapy, n (%)	43.0 (56.6)	23 (46.0)	20 (76.9)	0.010**
Costs (¥), median (IQR)	70,069.5	48,449.5	99,086.0	<0.001**
	(44,593.5-95,210.0)	(42,749.0-77,478.0)	(67,639.0-	
			113,486.0)	

167 SD, standard deviation; i-NIHSS, National Institute of Health Stroke Scale score at admission;

168 IQR, interquartile range; IV-tPA, intravenous tissue-type plasminogen activator; ** $p \le 0.05$.

169 **Recanalization and Clinical Outcome**

170 Safety and efficacy endpoint comparisons between the two groups are shown in Table 2. Overall,

171 98.7% (75/76) patients had grade 2b–3 eTICI, and one patient in the PMT group failed to

recanalize because of iatrogenic dissection. 65.8% (50/76) patients achieved 90-day functional

independence (mRS≤2), and 35.5% (27/76) patients achieved 90-day excellent functional

174	outcome (mRS≤1). The comparison of 90-day mRS score changes between the groups is shown
175	in Supplementary Figure 1. No significant differences were observed in the successful
176	revascularization rate (100% vs. 96.2%, p=.342), 90-day functional independence (72.0% vs.
177	53.8%, p=.551), symptomatic intracranial hemorrhage rate (12.0% vs. 15.4%, p>.999), and
178	mortality rate (10.0% vs. 7.7%, p>.999) between the two groups. However, the rates of FPR
179	(54.0% vs. 28.9%, p=.010), complete reperfusion (76.0% vs. 53.8%, p=.049), and 90-day
180	excellent functional outcomes (44.0% vs. 19.2%, p=.032) were significantly higher in the PBA
181	group than in the PMT group.

182

183	Table 2 Efficac	ey and safety	endpoint com	parisons betwee	en the two groups
-----	-----------------	---------------	--------------	-----------------	-------------------

	Overall	PBA group	PMT group	P value
	(n=76)	(n=50)	(n=26)	
FPR , n (%)	33 (43.4)	27 (54.0)	6 (28.9)	0.010**
eTICI , n (%)				
≥2b (2b,2c,3)	75 (98.7)	50 (100.0)	25 (96.2)	0.342
≥2c (2c,3)	52 (68.4)	38 (76.0)	14 (53.8)	0.049**
90-d mRS , n (%)				
0-1	27 (35.5)	22 (44.0)	5 (19.2)	0.032**
0-2	50 (65.8)	36 (72.0)	14 (53.8)	0.551
sICH , n (%)	10 (13.2)	6 (12.0)	4 (15.4)	>0.999
Mortality, n (%)	7 (9.2)	5 (10 0)	2 (7 7)	>0 999

184 FPR, first-pass recanalization; eTICI, expanded thrombolysis in cerebral ischemia; mRS,

185 modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; ** p≤0.05.

186

- 187 Multivariate logistic regression analysis revealed that the i-NIHSS and first-choice treatment
- 188 (PMT vs. PBA) were independent factors for 90-day excellent functional outcomes (adjusted
- 189 odds ratio [aOR]=.53, 95% confidence interval [CI]: .36–.76, p<0.001 and aOR=0.10, 95% CI:
- 190 0.02–0.66, p=.017, respectively). The results of the univariate and multivariate logistic
- 191 regression analyses are shown in Supplementary Table 1.
- 192
- 193 Supplementary Table 1 Logistic regression analysis for predicting 90-day excellent functional

194 outcome (mRS \leq 1)

	Univariate ana	Univariate analysis		Multivariate analysis	
Variable	OR (95% CI)	P value	aOR (95% CI)	P value	
Age	0.96 (0.92–1.01)	0.097*	0.94 (0.88-1.01)	0.081*	
Sex (Female vs. Male)	2.22 (0.76-6.53)	0.147	4.34 (0.74-25.44)	0104	
Vascular risk factors					
Hypertension	2.08 (0.60-7.15)	0.247		•••	
Diabetes mellitus	0.52 (0.20-1.38)	0.191	•••	•••	
Hyperlipidemia	1.09 (0.42-2.83)	0.867		•••	
Coronary artery disease	1.53 (0.37-6.26)	0.554		•••	
Smoking	0.52 (0.16-1.62)	0.256		•••	
History of stroke	0.88 (0.30-2.53)	0.805		•••	
Location of occlusion site	0.51 (0.18-1.43)	0.198		•••	
i-NIHSS	0.59 (0.45-0.78)	<0.001**	0.53 (0.36-0.76)	<0.001**	
IV-tPA	0.66 (0.25–1.74)	0.403		•••	
Glycoprotein IIb/IIIa use	0.42 (0.15-1.17)	0.096*	0.67 (0.15-3.02)	0.601	
General anesthesia	0.44 (0.17-1.16)	0.096*	0.49 (0.12-1.99)	0.319	
Means of recanalization					

Stent retrieval	0.85 (0.32-2.24)	0.747	•••	•••
Aspiration	NA	>0.999		•••
Balloon dilation	0.71 (0.15-3.44)	0.672		•••
Stenting	0.21 (0.07–0.62)	0.005**	0.33 (0.07-1.51)	0.152
First-choice treatment (PMT vs.	0.30 (0.10-0.93)	0.037**	0.10 (0.02-0.66)	0.017**
PBA)				

195 OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; i-NIHSS, National Institute of 196 Health Stroke Scale score at admission; IV-tPA, intravenous tissue-type plasminogen activator; 197 PBA, preferred balloon angioplasty; PMT, preferred mechanical thrombectomy; * $p \le 0.10$; ** 198 p≤0.05. 199 200 DISCUSSION 201 For patients with ICAS-ELVO involving the microcatheter "first-pass effect" during EVT, two 202 preferred treatments—MT and balloon angioplasty—were used for recanalization in this study. 203 Our results indicate that the two treatments were comparable in terms of safety. However, they 204 also show that balloon angioplasty, as the first-choice treatment, potentially increases the FPR 205 and complete reperfusion rates, shortens the puncture-to-recanalization time, reduces the rescue 206 therapy rate, and improves patients' 90-day outcomes. 207 MT is often accompanied by a lower recanalization rate, longer operation time, and a higher risk 208 of vascular reocclusion in patients with ICAS-ELVO, a phenomenon that has always challenged

- 209 neurointerventionalists. Owing to the special pathophysiological characteristics of ICAS-ELVO,
- 210 researchers are attempting to develop a targeted EVT strategy based on etiological diagnosis.
- 211 Certain studies have reported the advantages of direct angioplasty as a primary treatment for
- 212 ICAS-ELVO, including shortening the procedure time and reducing the number of procedure

device attempts, with similar safety to that of MT¹³¹⁴. However, these studies did not define the 213 214 clot burden of the included patients, thus potentially affecting the persuasiveness of the results. 215 ICAS-ELVO is related to in situ thrombotic occlusion, which results from unstable plaque 216 ruptures and typically has a smaller clot burden; however, it is not absolute. Studies have demonstrated that clot burdens are associated with patient prognosis after EVT¹⁹, and balloon 217 218 angioplasty, as the first-choice treatment for ICAS-ELVO, is often ineffective in cases of large 219 clot burdens. Thus, considering the clot burden as one of the bases for developing an EVT strategy for patients with ICAS-ELVO is recommended. Although the clot burden score ^{20 21} has 220 221 been used to evaluate clot burdens, its extensive and accurate evaluation in clinical practice 222 remains challenging. The microcatheter "first-pass effect" is a valuable predictor of ICAS-ELVO 223 based on the condition's small clot size and relative ease of disintegration; when the 224 microcatheter passes through the occlusive site, it pushes part of the fresh thrombus to the blood 225 vessel's distal end. Thus, the microcatheter "first-pass effect" may also be an effective indicator 226 of a small clot burden and an important variable for planning the ICAS-ELVO EVT strategy. 227 Rapid and complete reperfusion after thrombectomy is a predictor of favorable outcomes in ELVO stroke ¹⁶²². However, in patients with ICAS-ELVO, vessels tend to reocclude after 228 229 recanalization due to post-MT endothelial injury, and repeated MT and/or angioplasty must be 230 performed, thus substantially delaying reperfusion. Moreover, despite achieving successful 231 vessel recanalization after MT, a considerable number of patients fail to achieve complete 232 reperfusion because of residual stenosis. In this study, we compared the rates of FPR, complete 233 reperfusion (eTIC $\geq 2c$), and 90-day excellent functional outcomes (mRS ≤ 1) between PBA and 234 PMT patients with ICAS-ELVO involving the microcatheter "first-pass effect" during EVT. The 235 results revealed that balloon angioplasty, as the first-choice treatment, potentially increases the

236 FPR and complete reperfusion rates and shortens the puncture-to-recanalization time; moreover, 237 the puncture-to-recanalization time and FPR rate were significantly correlated with 90-day 238 excellent functional outcomes. Our study implies that, for patients with ICAS-ELVO, balloon 239 angioplasty that entails selecting an appropriate balloon size and dilatation pressure for 240 angioplasty may be less invasive to the vascular endothelium than MT, which is beneficial for 241 maintaining vascular stability after the first recanalization. 242 EVT is recognized as an effective method for ELVO and has been increasingly promoted 243 worldwide. However, cost is often an important consideration for families and patients when 244 deciding on EVT, especially for self-funded patients with ICAS-ELVO. Given the complexity of 245 MT for ICAS-ELVO, neurointerventionalists often tend to estimate relatively high surgical costs, 246 thus further increasing the concern of the patient's family. Previous studies have observed that 247 direct balloon angioplasty can reduce the number of procedure device attempts in patients with 248 ICAS-ELVO; however, its ability to alleviate surgical costs has not been discussed. Our results 249 indicate that balloon angioplasty, as the first-choice treatment, potentially reduces the use of 250 remedial measures, thus relieving the economic burden on patients with ICAS-ELVO. 251 Considering that approximately one-third of ischemic strokes in Asia are caused by ICAS, ensuring the effectiveness of EVT while reducing the cost as much as possible will benefit a 252 253 greater number of patients. 254 Emergency balloon angioplasty's major cause for concern is its increased risk of reocclusion 255 without adequate antiplatelet therapy or cerebral hemorrhage when antiplatelet therapy is 256 administered within 24 h of intravenous thrombolysis. Tirofiban is a short-acting intravenous

the combined use of tirofiban during or before EVT is feasible in patients with ICAS-ELVO^{11 23-}

antiplatelet drug widely used in percutaneous coronary intervention, and studies have proven that

257

²⁵. Furthermore, tirofiban may be an alternative therapy for patients with post-MT ICAS-ELVO 259 260 26 . In this study, we found that balloon angioplasty, as the first-choice treatment, neither 261 increased tirofiban use nor amplified the risk of symptomatic intracranial hemorrhage. In 262 contrast, tirofiban use was more aggressively required in the PMT group owing to endothelial 263 injury caused by additional and repeat MT. Another cause for concern in balloon angioplasty is 264 the "snowplowing" effect: branch occlusion following angioplasty may cause secondary 265 ischemia in the injury site. However, because the territory supplied by the neighboring side 266 branches is often already infarcted following the complete occlusion of the trunk vessel, the risk of secondary ischemic injury due to "snowplowing" is not as high as anticipated⁸. 267 268 Planning a targeted EVT strategy based on etiological diagnosis is an attractive option; however, 269 predicting the etiology of vascular occlusion promptly and accurately before EVT remains 270 difficult. Currently, no widely accepted diagnostic criteria for distinguishing atherothrombotic 271 ELVO from others and potential preprocedural methods for identifying signs of atherosclerosis 272 are available. For example, patients repeatedly suffering from transient ischemic attack-related 273 symptoms on the ipsilateral side before acute ischemic stroke, combined with risk factors 274 associated with atherosclerosis, have exhibited lower NIHSS scores and favorable collateral circulation upon admission, which leads to the suspicion of ICAS-ELVO⁹. Imaging predictors, 275 276 such as a core infarction located in the watershed area, severe calcification at the site of occlusion, severe and/or multifocal narrowing on angiography, "tapered" occlusion²⁷, "truncal-277 type" occlusion ²⁸, and the microcatheter "first-pass effect," ¹⁵ all support ICAS as the most 278 279 likely etiology. In the future, more diagnostic methods that enable the rapid and accurate 280 diagnosis of vascular occlusion's etiology and provide a basis for treatment decisions are 281 warranted.

282 Limitations

283	There were several limitations in this study. First, our findings should be cautiously interpreted,
284	as the study is characterized by a small sample size, single center, and retrospective nature;
285	therefore, further prospective, multicenter, large sample-sized studies are required. Second,
286	although a small clot burden is the prerequisite for the existence of microcatheter "first-pass
287	effect," its specificity and sensitivity to predict small clot burden need to be further tested in
288	more studies.
289	
290	CONCLUSION
291	Our study reveals that balloon angioplasty, as the first-choice treatment, is potentially beneficial
292	in improving the rate of 90-day excellent functional outcomes, shortening the procedure time,
293	and reducing surgical costs for patients with ICAS-ELVO involving the microcatheter "first-pass
294	effect" during EVT. In the future, the rapid and accurate diagnosis of the etiology and clot
295	burden of ELVO and development of an individualized EVT strategy based on etiology and clot
296	burden will be the focus of our subsequent research.
297	
298	Conflict of Interest: None.
299	
300	Disclosure of Funding: None.
301	
302	Acknowledgments: We are grateful to the clinicians and staff at the Shenzhen Hospital of

303 Southern Medical University who contributed to the medical intervention and data collection for

304	this study. We would like to thank Editage (www.editage.cn) for English language editing and
305	Charlesworth (www.cwauthors.com.cn) for statistical review.
306	
307	
308	Author Contributions: L.Z. and X.H. analyzed and interpreted the data and drafted the
309	manuscript. Y.L. conceived and designed the research. M.P. and K.L. evaluated the image. L.L.
310	and L.H. made critical revisions of the manuscript. All authors read and approved the final
311	manuscript.
312	
313	Ethical Statement: The studies involving human participants were reviewed and approved by
314	the Clinical Research Ethics Committee of Shenzhen Hospital of Southern Medical University.
315	The patients/participants provided written informed consent to participate in this study.
316	
317	Data Availability Statement: The datasets used and/or analyzed during the current study are
318	available from the corresponding author on reasonable request.
319	
320	REFERENCES
321	1. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for
322	acute ischemic stroke. N Engl J Med 2015;372(1):11-20. doi: 10.1056/NEJMoa1411587
323	2. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with
324	perfusion-imaging selection. N Engl J Med 2015;372(11):1009-18. doi:
325	10.1056/NEJMoa1414792 [published Online First: 2015/02/12]

- 326 3. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular
- treatment of ischemic stroke. N Engl J Med 2015;372(11):1019-30. doi:
- 328 10.1056/NEJMoa1414905 [published Online First: 2015/02/12]
- 329 4. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-
- 330 PA alone in stroke. N Engl J Med 2015;372(24):2285-95. doi: 10.1056/NEJMoa1415061
- 331 5. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in
- 332 ischemic stroke. N Engl J Med 2015;372(24):2296-306. doi: 10.1056/NEJMoa1503780
- 6. Kim YW, Hong JM, Park DG, et al. Effect of intracranial atherosclerotic disease on
- and ovascular treatment for patients with acute vertebrobasilar occlusion. AJNR Am J
- 335 Neuroradiol 2016;37(11):2072-8. doi: 10.3174/ajnr. A4844 [published Online First: 2016/06/18]
- 336 7. Hwang YH, Kim YW, Kang DH, et al. Impact of target arterial residual stenosis on outcome
- after endovascular revascularization. Stroke 2016;47(7):1805-7. doi:
- 338 10.1161/STROKEAHA.116.014694
- 8. Lee JS, Lee SJ, Hong JM, et al. Endovascular Treatment of Large Vessel Occlusion Strokes
- 340 Due to Intracranial Atherosclerotic Disease. J Stroke 2022;24(1):3-20. doi:
- 341 10.5853/jos.2021.01375 [published Online First: 2022/02/09]
- 342 9. Tsang ACO, Orru E, Klostranec JM, et al. Thrombectomy outcomes of intracranial
- 343 atherosclerosis-related occlusions. Stroke 2019;50(6):1460-6. doi:
- 344 10.1161/STROKEAHA.119.024889 [published Online First: 2019/05/16]
- 345 10. Kang DH, Yoon W. Current Opinion on Endovascular Therapy for Emergent Large Vessel
- 346 Occlusion Due to Underlying Intracranial Atherosclerotic Stenosis. Korean J Radiol
- 347 2019;20(5):739-48. doi: 10.3348/kjr.2018.0809 [published Online First: 2019/04/18]

- 348 11. Jia B, Feng L, Liebeskind DS, et al. Mechanical thrombectomy and rescue therapy for
- 349 intracranial large artery occlusion with underlying atherosclerosis. J Neurointerv Surg
- 2018;10(8):746-50. doi: 10.1136/neurintsurg-2017-013489 [published Online First: 2017/12/06]
- 351 12. Zhang J, Jia B, Pan Y, et al. A comparison between different endovascular treatment
- 352 strategies for acute large vessel occlusion due to intracranial artery atherosclerosis: data from
- 353 ANGEL-ACT Registry. Neuroradiology 2022;64(8):1627-38. doi: 10.1007/s00234-022-02933-w
- 354 [published Online First: 2022/03/30]
- 355 13. Ma G, Sun X, Tong X, et al. Safety and Efficacy of Direct Angioplasty in Acute Basilar
- 356 Artery Occlusion Due to Atherosclerosis. Front Neurol 2021; 12:651653. doi:
- 357 10.3389/fneur.2021.651653 [published Online First: 2021/08/06]
- 358 14. Luo Y, Huang J, Yang Y, et al. Effect of direct angioplasty therapy on acute middle cerebral
- artery occlusion with good leptomeningeal collateral. Clin Neurol Neurosurg 2020; 190:105744.
- 360 doi: 10.1016/j.clineuro.2020.105744 [published Online First: 2020/02/28]
- 361 15. Yi TY, Chen WH, Wu YM, et al. Microcatheter "First-Pass Effect" Predicts Acute
- 362 Intracranial Artery Atherosclerotic Disease-Related Occlusion. Neurosurgery 2019;84(6):1296-
- 363 305. doi: 10.1093/neuros/nyy183 [published Online First: 2018/05/24]
- 16. McTaggart RA, Ospel JM, Psychogios MN, et al. Optimization of endovascular therapy in
- the neuroangiography suite to achieve fast and complete (Expanded treatment in cerebral
- 366 ischemia 2c-3) reperfusion. Stroke 2020;51(7):1961-8. doi: 10.1161/STROKEAHA.119.026736
- 367 [published Online First: 2020/06/23]
- 368 17. Almekhlafi MA, Mishra S, Desai JA, et al. Not all "successful" angiographic reperfusion
- 369 patients are an equal validation of a modified TICI scoring system. Interv Neuroradiol
- 370 2014;20(1):21-7. doi: 10.15274/INR-2014-10004 [published Online First: 2014/02/22]

- 18. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever
- in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority
- trial. Lancet 2012;380(9849):1241-9. doi: 10.1016/S0140-6736(12)61384-1
- 19. Treurniet KM, Yoo AJ, Berkhemer OA, et al. Clot Burden Score on Baseline Computerized
- 375 Tomographic Angiography and Intra-Arterial Treatment Effect in Acute Ischemic Stroke. Stroke
- 376 2016;47(12):2972-78. doi: 10.1161/STROKEAHA.116.014565 [published Online First:
- 377 2016/11/09]
- 20. Derraz I, Bourcier R, Soudant M, et al. Does clot burden score on baseline T2*-MRI impact
- 379 clinical outcome in acute ischemic stroke treated with mechanical thrombectomy? J Stroke
- 380 2019;21(1):91-100. doi: 10.5853/jos.2018.01921 [published Online First: 2019/02/09]
- 381 21. Derraz I, Pou M, Labreuche J, et al. Clot burden score and collateral status and their impact
- 382 on functional outcome in acute ischemic stroke. AJNR Am J Neuroradiol 2021;42(1):42-8. doi:
- 383 10.3174/ajnr. A6865 [published Online First: 2020/11/14]
- 384 22. Nikoubashman O, Dekeyzer S, Riabikin A, et al. True first-pass effect. Stroke
- 385 2019;50(8):2140-6. doi: 10.1161/STROKEAHA.119.025148 [published Online First:
- 386 2019/06/21]
- 387 23. Yoon W, Kim SK, Park MS, et al. Endovascular treatment and the outcomes of
- 388 atherosclerotic intracranial stenosis in patients with hyperacute stroke. Neurosurgery
- 2015;76(6):680-6; discussion 86. doi: 10.1227/NEU.00000000000694 [published Online First:
 2015/05/20]
- 391 24. Kim YW, Sohn SI, Yoo J, et al. Local tirofiban infusion for remnant stenosis in large vessel
- 392 occlusion: tirofiban ASSIST study. BMC Neurol 2020;20(1):284. doi: 10.1186/s12883-020-
- 393 01864-4 [published Online First: 2020/07/22]

- 394 25. Investigators RBT, Qiu Z, Li F, et al. Effect of Intravenous Tirofiban vs Placebo Before
- 395 Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The
- 396 RESCUE BT Randomized Clinical Trial. JAMA 2022;328(6):543-53. doi:
- 397 10.1001/jama.2022.12584 [published Online First: 2022/08/10]
- 26. Kang DH, Yoon W, Kim SK, et al. Endovascular treatment for emergent large vessel
- 399 occlusion due to severe intracranial atherosclerotic stenosis. J Neurosurg 2018:1-8. doi:
- 400 10.3171/2018.1. JNS172350 [published Online First: 2018/06/23]
- 401 27. Liang W, Wang Y, Du Z, et al. Intraprocedural angiographic signs observed during
- 402 endovascular thrombectomy in patients with acute ischemic stroke: a systematic review.
- 403 Neurology 2021;96(23):1080-90. doi: 10.1212/WNL.00000000012069 [published Online
- 404 First: 2021/04/25]
- 405 28. Baek JH, Kim BM. Angiographical Identification of Intracranial, Atherosclerosis-Related,
- 406 Large Vessel Occlusion in Endovascular Treatment. Front Neurol 2019; 10:298. doi:
- 407 10.3389/fneur.2019.00298 [published Online First: 2019/05/02]
- 408

409 FIGURE LEGENDS

410 **Figure 1.** Flow chart of patient screening in this study

411 Figure 2. Illustrative cases of the microcatheter "first-pass effect." (1): A 51-year-old male

- 412 patient with hypertension and diabetes for 5 years presented with an acute onset of left body
- 413 weakness (iNIHSS score: 9) for 11 h. Angiography revealed occlusion at the M1 segment of the
- 414 right MCA and "taper sign" (A); Angiography exhibited adequate collateral, and retro-flow
- 415 reconstituted the distal portion of M1 (**B**); An XT-27 microcatheter and a microwire were
- 416 navigated through the occlusion area to the distal patent artery, and the microcatheter was

- 417 subsequently withdrawn to the occlusion's proximal side. Angiography demonstrated blood flow
- 418 through the vessel at the occlusion site, which was defined as the microcatheter "first-pass
- 419 effect" (C); Direct balloon angioplasty (gateway 2.0×9.0 mm) achieved an mTICI score of 3
- 420 (D). (2): A 65-year-old male patient with hypertension for 11 years presented with
- 421 unconsciousness (iNIHSS score: 15) for 4 h. Angiography demonstrated that the V5 segment of
- 422 the right dominant vertebral artery was occluded (E); Angiography revealed the microcatheter
- 423 "first-pass effect" (F); Direct balloon angioplasty (Sino 2.25 × 15.0 mm) achieved an mTICI
- 424 score of 2b with focal dissection (G); An enterprise stent (4×39 mm) was placed at the stenotic
- 425 site, and angiography revealed an mTICI score of 3 (**H**).
- 426 Supplementary Figure 1. Comparison of modified Rankin Scale (mRS) scores at 90 days
- 427 between the two groups



